<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109147</url>
  </required_header>
  <id_info>
    <org_study_id>2009-017673-38</org_study_id>
    <nct_id>NCT01109147</nct_id>
  </id_info>
  <brief_title>Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients</brief_title>
  <official_title>Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients During Emotional Tasks and With Reference to Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qualissima</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qualissima</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After an initial screening visit, including an assessment of psychiatric disorders, patients
      stabilized on antipsychotic medication (aripiprazole or risperidone) for at least 6 weeks and
      control subjects will undergo an assessment using functional magnetic resonance imaging
      (fMRI) of the differences of patterns of brain activation during an emotional task
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is: interventional, comparative, open label, multi center, without experimental
      treatment.

      Main objective: To evaluate the effect of aripiprazole and risperidone on brain activation
      during an emotional task of matching patients with schizophrenia, and in reference to control
      subjects.

      Secondary Objective: Comparison of emotional subjective and physiological perception in
      patients with schizophrenia in relation with their treatment. Comparison of brain activation
      in patients during the emotional induction task based on symptomatic dimensions, personality
      traits and performance on cognitive and attentional tests, and for insight capacity .
      Comparison of transcript level of candidate genes in blood mononuclear cells between the
      study groups and study the interactions between the observed differences in brain imaging and
      different levels of transcription of these genes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI)</measure>
    <time_frame>3 days after the decision of inclusion</time_frame>
    <description>During the fMRI session, the activation of each brain circuits is measured by a &quot;Bold signal&quot; (an arbitrary measure of contrast: numbers of voxels highlighted/activated in the region of interest).
The emotional task is composed by congruent and incongruent images. Three effects were caused by the task: congruence, attention and valence effects. Each of them affect, involve and activate the regions of interests differentially within the differents arms.
The region of interests who were mainly observed are: Anterior Cingulate Cortex (ACC), Prefrontal dorso-lateral Cortex (PFdlC) and the Amygdala (A).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Emotional Reactivity</measure>
    <time_frame>3 days after the decision of inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Cognitive and Attentional Abilities</measure>
    <time_frame>3 days after the decision of inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Personality Traits</measure>
    <time_frame>3 days after the decision of inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the Level of Expression of Candidate Genes</measure>
    <time_frame>one blood sample</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Schizophrenia, Undifferentiated Type</condition>
  <arm_group>
    <arm_group_label>aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imagery: A fMRI session is conducted on schizophrenic patients under aripiprazole (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).
Genetic: pharmacogenetic sampling. One sample was collected for each subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imagery: A fMRI session is conducted on schizophrenic patients under rsiperidone (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).
Genetic: pharmacogenetic sampling. One sample was collected for each subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Imagery: A fMRI session is conducted on healthy volunteers. Genetic: pharmacogenetic sampling. One sample was collected for each subject.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imagery</intervention_name>
    <description>All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.</description>
    <arm_group_label>aripiprazole</arm_group_label>
    <arm_group_label>risperidone</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>pharmacogenetic sampling</intervention_name>
    <description>A pharmacogenetic sample will be done with an additional consentment.</description>
    <arm_group_label>aripiprazole</arm_group_label>
    <arm_group_label>risperidone</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For patients

               1. Men and women, right handed, 18 to 45 years;

               2. Having given their written informed consent;

               3. Presenting a diagnosis of schizophrenia made by DMS IV, hospitalized or followed
                  regularly in a hospital proper, and whose symptoms are stable for at least 6
                  weeks, at the discretion of the psychiatrist;

               4. Receiving antipsychotic treatment (risperidone or aripiprazole) monotherapy
                  stable (treatment and dose) for at least than 6 weeks;

               5. Showing no contra-indication for fMRI;

               6. Patients whose physical examination is unremarkable clinically significant;

               7. Patients without serious somatic pathology;

               8. Affiliated to a social security system.

               9. For women of childbearing potential, an appropriate contraception is mandatory
                  and an negative pregnancy test

          -  For controls

               1. Men and women, right handed, aged 18 to 45 years of age, sex and
                  socio-educational level comparable to patients included;

               2. Having given their written informed consent;

               3. Do not present a diagnosis of schizophrenia according to DSM IV set;

               4. Do not present psychiatric history, and free of any psychotropic medication;

               5. Including the physical examination is unremarkable clinically significant;

               6. Having no professional musical practice;

               7. Affiliated with a social security system.

        Exclusion Criteria:

          -  For patients

               1. Patients in menstruation without effective contraception (oral, intramuscular
                  hormonal, intrauterine device, or surgical);

               2. Patients who are pregnant or breastfeeding;

               3. Patients not meeting criteria for schizophrenia according to DSM IV criteria or
                  those with resistant schizophrenia (Kane criteria);

               4. Introducing a somatic disease or serious neurological, particularly Parkinson's
                  disease, epilepsy, tardive dyskinesia and disabling cardiovascular disease, liver
                  or kidney disease;

               5. Presenting a contra-indication to MRI;

               6. Having a history of alcoholism or drug addiction during the past year;

               7. Participating in another clinical trial or are in a period of exclusion from a
                  previous protocol;

               8. Patients likely to have behavioral self aggression from the trial investigators

                  During the study:

               1. The investigator considers, for safety reasons, it is in the interest of the
                  patient to be excluded from the study (Hospital readmission due to psychotic
                  symptoms, clinical or psychiatric reasons)

               2. Consentment withdrawal

               3. The patient does not longer correspond to the inclusion criteria or protocol
                  requirements

          -  For controls

               1. Women of childbearing potential without effective contraception (oral,
                  intramuscular hormonal, intrauterine device, or surgical);

               2. Pregnant or breastfeeding;

               3. Presenting a somatic, psychiatric or neurological disorder;

               4. Presenting a history of alcohol or substance abuse during the past year;

               5. Participating in another clinical trial or are in a period of exclusion from a
                  previous protocol;

               6. Presenting a contra-indication to MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Blin, professor</last_name>
    <role>Study Director</role>
    <affiliation>study coordinator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HÃ´pital de la Conception - Service du Pr Dassa -147, boulevard Baille</name>
      <address>
        <city>Marseille cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sainte-Marguerite Hospital - Psychiatric service -Service du Pr Azorin - 270 boulevard de Sainte Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <results_first_submitted>August 29, 2013</results_first_submitted>
  <results_first_submitted_qc>March 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2014</results_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenic Disorders</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Affect</keyword>
  <keyword>Emotional Blunting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aripiprazole</title>
          <description>Schizophrenic patient stabilized under aripiprazole for six weeks before inclusion</description>
        </group>
        <group group_id="P2">
          <title>Risperidone</title>
          <description>Schizophrenic patient stabilized under risperidone for six weeks before inclusion</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>healthy volunteers</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15">2 have been excluded of the results</participants>
                <participants group_id="P2" count="11">3 have been excluded of the results</participants>
                <participants group_id="P3" count="26">10 have been excluded of the results</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The number of participants was calculated as an estimation, due to no previous known results in this field of research.</population>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole</title>
          <description>Schizophrenic patient stabilized under aripiprazole for six weeks before inclusion</description>
        </group>
        <group group_id="B2">
          <title>Risperidone</title>
          <description>Schizophrenic patient stabilized under risperidone for six weeks before inclusion</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>healthy volunteers</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" spread="9.6"/>
                    <measurement group_id="B2" value="31.6" spread="9.2"/>
                    <measurement group_id="B3" value="32.9" spread="7.8"/>
                    <measurement group_id="B4" value="33.1" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Emotional Reactivity</title>
        <time_frame>3 days after the decision of inclusion</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Cognitive and Attentional Abilities</title>
        <time_frame>3 days after the decision of inclusion</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Personality Traits</title>
        <time_frame>3 days after the decision of inclusion</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigate the Level of Expression of Candidate Genes</title>
        <time_frame>one blood sample</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI)</title>
        <description>During the fMRI session, the activation of each brain circuits is measured by a &quot;Bold signal&quot; (an arbitrary measure of contrast: numbers of voxels highlighted/activated in the region of interest).
The emotional task is composed by congruent and incongruent images. Three effects were caused by the task: congruence, attention and valence effects. Each of them affect, involve and activate the regions of interests differentially within the differents arms.
The region of interests who were mainly observed are: Anterior Cingulate Cortex (ACC), Prefrontal dorso-lateral Cortex (PFdlC) and the Amygdala (A).</description>
        <time_frame>3 days after the decision of inclusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Schizophrenic patient stabilized under aripiprazole for six weeks before inclusion</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Schizophrenic patient stabilized under risperidone for six weeks before inclusion</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI)</title>
          <description>During the fMRI session, the activation of each brain circuits is measured by a &quot;Bold signal&quot; (an arbitrary measure of contrast: numbers of voxels highlighted/activated in the region of interest).
The emotional task is composed by congruent and incongruent images. Three effects were caused by the task: congruence, attention and valence effects. Each of them affect, involve and activate the regions of interests differentially within the differents arms.
The region of interests who were mainly observed are: Anterior Cingulate Cortex (ACC), Prefrontal dorso-lateral Cortex (PFdlC) and the Amygdala (A).</description>
          <units>arbitrary units of activation</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Activation of Anterior Cingulate Cortex (ACC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="2.8"/>
                    <measurement group_id="O2" value="-0.21" spread="3.1"/>
                    <measurement group_id="O3" value="3.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activation of Prefrontal dorso-lateral Cortex (PF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="3.0"/>
                    <measurement group_id="O2" value="-0.3" spread="4.0"/>
                    <measurement group_id="O3" value="5.3" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessment of adverse event at each visit (2 times on approximately one week).</time_frame>
      <desc>Assessment of adverse event has been run by the investiagtor at each visit (2 times) during the entire participation of the subject (approximately one week).</desc>
      <group_list>
        <group group_id="E1">
          <title>Aripiprazole</title>
          <description>Schizophrenic patient stabilized under aripiprazole for six weeks before inclusion</description>
        </group>
        <group group_id="E2">
          <title>Risperidone</title>
          <description>Schizophrenic patient stabilized under risperidone for six weeks before inclusion</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>healthy volunteers</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <description>after a blood puncture</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All results and publications are reviewed by the sponsor and the principle Investigator. None could be released without accordance from both parts.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eric Fakra</name_or_title>
      <organization>Hopital Sainte Marguerite - APHM - Service du Pr. Azorin</organization>
      <email>eric.fakra@ap-hm.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

